Last reviewed · How we verify
Colestid (Colestipol)
Colestid (Colestipol) is a bile acid sequestrant, a small molecule drug class, originally developed by Pharmacia and Upjohn and currently owned by Pfizer. It was FDA-approved in 1977 for the treatment of hypercholesterolemia and hyperlipidemia. Colestid is off-patent and has multiple generic manufacturers. It works by binding to bile acids in the gastrointestinal tract, preventing their reabsorption and thereby reducing cholesterol levels in the blood. As an off-patent medication, Colestid is widely available in generic forms.
At a glance
| Generic name | Colestipol |
|---|---|
| Also known as | Colestid |
| Sponsor | Pfizer |
| Drug class | Bile Acid Sequestrant |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1977 |
Approved indications
- Hypercholesterolemia
- Hyperlipidemia
Common side effects
- Constipation
- Abdominal discomfort
- Intestinal gas
- Bloating and flatulence
- Indigestion
- Heartburn
- Diarrhea
- Loose stools
- Nausea
- Vomiting
- Bleeding hemorrhoids
- Blood in the stool
Drug interactions
- propranolol
- chlorothiazide
- tetracycline
- furosemide
- penicillin G
- hydrochlorothiazide
- gemfibrozil
- aspirin
- clindamycin
- clofibrate
- methyldopa
- nicotinic acid (niacin)
Key clinical trials
- The Precision CAD Trial (NA)
- Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea (PHASE4)
- An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide (PHASE2)
- Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride (PHASE1)
- Sorbent Therapy of the Cutaneous Porphyrias (PHASE2,PHASE3)
- Familial Atherosclerosis Treatment Study (PHASE3)
- A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction (PHASE4)
- Cholesterol-Lowering Atherosclerosis Study (CLAS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colestid CI brief — competitive landscape report
- Colestid updates RSS · CI watch RSS
- Pfizer portfolio CI